Healthcare questions with answers
Explain why you think the patient presented the symptoms described
The response was due to the inflammation of the cells when he took the medication, the body reacted towards the response of the medication, and the cells displayed. The immunosuppressant that the patient had taken for rheumatoid arthritis would not respond effectively to the virus that had infected the patient and additional illness such as the hemoptysis that the patient is suffering from is the one that caused serious symptoms due to the reaction with the medicine that he had taken. In the other case, the medication may be had not yet functioned well to the illness since the effective reaction of the treatment that he had taken takes about two weeks to have complete action on the bacteria or virus that is causing diseases (Smolen, at el 2016). This would not be a stopping point of taking medication or changing the prescription that the patient was talking he has to finish the dose first them take a keen observation on how he will be in terms of his health status.
Identify the genes that may be associated with the development of rheumatoid arthritis
The variations of human leukocyte antigen majorly the HLA-DRB1 gene. The HLA genes produce proteins that help the immune system to different proteins that are contained in the body and invaders, such as viruses and bacteria (Wu at el 2016). The complex structure of the HLA-DRB1 genotype has the association of the development of the disease RA. The association of the HLA-DRB1*13 plus DRB*15 is linked to the production of the ACPA that was discovered in Hungarian patients. These genes and alleles that are combined under simulations of the disease have been associated with rheumatoid arthritis to its development and treatment that is not supposed to have other medications that will alter its functioning in the patient’s body.
Explain the process of immunosuppression and the effect it has on body systems
Immunosuppression is the minimization of the activities and effects of the immune system. Some section of the immune system has the immunosuppressive impacts on the effect of the immune system, and this condition can occur because of the reactions that happen when a person is undertaking treatment of the disease. The induction of immunosuppression is done to protect the body from rejecting an organ transplant.
During the administration of immunosuppression, drugs are targeted at the hyperactive components that are contained in the immune system. Patients who have cancer cells have to be subjected to radiotherapy before they are prescribed to the medication. Drugs of immunosuppressive have a high potential that can cause immunodeficiency that results in susceptibility that will happen to opportunistic diseases and result in reduced cancer immunosurveillance (Stoffer at el 2016). The immunosuppressant is prescribed when a person has a normal response in his immune system.
The steroids are the first immunosuppressant that is identified; nevertheless, it has side effects that are limited to the use. The specific azathioprine is put in the procedure to allow more expansion of transplantation that will help to less match the donor pairs that are required for the transplant. It helps in accomplishing induction therapy that is initiated when there is a transplant is taking place. The induction therapy has the involvement of administration of high potent immunosuppressive antibiotics that will help protect the T-cell activations that will cause more damage to body cells when they are not well administered (Ogdie at el 2015). The disclose will help have a closure of having the best way of having the dose and merits of the best dose that will be administered by the medic to the patients. When the patient has taken medicine he develops the antibodies that will help him cover up the situation of having developed another effect alongside the current situation that is being treated.
Genetics is the main influence of the development of the rheumatoid arthritis disease that is familial risks result to the seropositive rheumatoid arthritis that happens within families that results to the establishment of familial risk contributions of seropositive that has a percentage of around 50% content of the seropositive rheumatoid arthritis (Allam, at el 2015). This disease mainly attacks some racial groups in North American natives who have established prevalence rates on rheumatoid arthritis to 7%. There are many alleles that are said to have the shared epitope; examples of the alleles include HLA DRB1, and the nomenclature shows that the classification of the system of the shared epitopes such HLADRB1*0404 has high risks of infecting a large area of population.
Pathophysiological processes that may be associated with the development of the diagnosed condition
The diagnosed condition can be associated with the multiple sclerosis condition that is involved in the central nervous system whose qualifiers are the T-cell mediated process (Ajeganova at el 2017). The immunopathological evidence of Multiple sclerosis indicates that the many types of pathological types that do not agree with T-cells and mediated disease. They also start to describe the T-cells and the cytokine that cause inflammations like the diagnosed disease. Through these samples, the disease has a high sample of making the genes have different responses to the body and the way it affects the body functions when the disease is being diagnosed. The two conditions involve genes and inheritance of the cells that multiply out of condition.
Reference
Ajeganova, S., & Huizinga, T. (2017). Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Therapeutic advances in musculoskeletal disease, 9(10), 249-262.Retrieved from: https://journals.sagepub.com/doi/full/10.1177/1759720X17720366
Allam, A., Kostova, Z., Nakamoto, K., & Schulz, P. J. (2015). The effect of social support features and gamification on a Web-based intervention for rheumatoid arthritis patients: a randomized controlled trial. Journal of medical Internet research, 17(1), e14.Retrieved from: https://www.jmir.org/2015/1/e14
Ogdie, A., Yu, Y., Haynes, K., Love, T. J., Maliha, S., Jiang, Y., … & Choi, H. (2015). Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis, and rheumatoid arthritis: a population-based cohort study. Annals of the rheumatic diseases, 74(2), 326-332.Retrieved from: https://ard.bmj.com/content/74/2/326.short
Smolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V., Dougados, M., Emery, P., … & Scholte-Voshaar, M. (2016). Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the rheumatic diseases, 75(1), 3-15.Retrieved from: https://ard.bmj.com/content/76/6/960.abstract
Stoffer, M. A., Schools, M. M., Smolen, J. S., Aletaha, D., Breedveld, F. C., Burmester, G., … & Gomez-Reino, J. (2016). Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Annals of the rheumatic diseases, 75(1), 16-22.Retrieved from: https://ard.bmj.com/content/75/1/16?papetoc=&utm_source=TrendMD&utm_medium=cpc&utm_campaign=ARD_TrendMD-0
Wu, X., He, B., Liu, J., Feng, H., Ma, Y., Li, D., … & Tian, J. (2016). Molecular insight into gut microbiota and rheumatoid arthritis. International journal of molecular sciences, 17(3), 431.Retrieved from: https://www.mdpi.com/1422-0067/17/3/431